NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy EndpointsPRNewsWire • 12/05/23
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023PRNewsWire • 12/04/23
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 11/28/23
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial ReadinessPRNewsWire • 11/13/23
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS ConferencesPRNewsWire • 11/09/23
NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023PRNewsWire • 11/06/23
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeCAccesswire • 10/19/23
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC ModelPRNewsWire • 10/04/23
NeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.PRNewsWire • 09/14/23
NeuroSense Announces Second Quarter 2023 Financial Results and Provides Business UpdatePRNewsWire • 08/16/23
NeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers SummitPRNewsWire • 07/11/23
NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023PRNewsWire • 06/01/23
NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker StudyPRNewsWire • 05/02/23
NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% EnrollmentPRNewsWire • 04/17/23
NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALSPRNewsWire • 03/27/23
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy ConferencePRNewsWire • 03/23/23